Healthcare of Ontario Pension Plan Trust Fund decreased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 41.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 138,468 shares of the company's stock after selling 99,532 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned 0.14% of Intellia Therapeutics worth $3,099,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in NTLA. Avidity Partners Management LP raised its stake in Intellia Therapeutics by 18.0% during the 4th quarter. Avidity Partners Management LP now owns 447,434 shares of the company's stock valued at $13,642,000 after acquiring an additional 68,334 shares in the last quarter. Orchard Capital Management LLC raised its stake in Intellia Therapeutics by 6.8% during the 4th quarter. Orchard Capital Management LLC now owns 170,006 shares of the company's stock valued at $5,183,000 after acquiring an additional 10,851 shares in the last quarter. Opaleye Management Inc. bought a new stake in Intellia Therapeutics during the 4th quarter valued at $3,019,000. Goldman Sachs Group Inc. raised its stake in Intellia Therapeutics by 3.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 824,527 shares of the company's stock valued at $25,140,000 after acquiring an additional 28,264 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Intellia Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company's stock valued at $254,514,000 after acquiring an additional 155,579 shares in the last quarter. Institutional investors own 88.77% of the company's stock.
Insider Activity at Intellia Therapeutics
In related news, CAO Michael P. Dube sold 2,012 shares of the business's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 3.00% of the company's stock.
Intellia Therapeutics Stock Performance
Shares of Intellia Therapeutics stock traded down $0.15 during trading on Monday, reaching $17.84. The company's stock had a trading volume of 1,598,794 shares, compared to its average volume of 1,522,268. The business's fifty day moving average price is $21.82 and its 200-day moving average price is $23.41. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -3.33 and a beta of 1.76. Intellia Therapeutics, Inc. has a one year low of $17.43 and a one year high of $34.87.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. The business's revenue for the quarter was down 48.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.40) EPS. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.22 EPS for the current year.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Evercore ISI upgraded Intellia Therapeutics to a "strong-buy" rating in a research report on Friday, August 9th. Stifel Nicolaus lowered their price target on Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating on the stock in a research report on Wednesday, September 11th. Truist Financial restated a "buy" rating and issued a $120.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. Canaccord Genuity Group restated a "buy" rating and issued a $73.00 target price on shares of Intellia Therapeutics in a report on Thursday, June 27th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $54.00 target price on shares of Intellia Therapeutics in a report on Thursday, September 19th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $61.77.
Check Out Our Latest Stock Report on NTLA
Intellia Therapeutics Profile
(
Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
See Also
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
